Risk of Thrombosis during and after a SARS-CoV-2 Infection: Pathogenesis, Diagnostic Approach, and Management

Sutanto, Henry; Soegiarto, Gatot

doi:10.3390/hematolrep15020024

Cited by 21 publications

(11 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, it has been suggested that COVID-19 infection can induce hypercoagulation, potentially contributing to pulmonary embolism, deep venous thrombosis, and the development of NBTE [7,8,[11][12][13].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Non-bacterial Thrombotic Endocarditis (NBTE) in the Absence of Malignancy or Lupus Anticoagulant/Antiphospholipid Antibodies: A Case Report

Patrzałek,

Zawada,

Stolarski

et al. 2024

Cureus

View full text Add to dashboard Cite

Non-bacterial thrombotic endocarditis (NBTE) is a very rare condition characterized by sterile thrombi formation on cardiac valves and is often associated with hypercoagulation states, such as malignancy and autoimmune disorders.We present the case of a 74-year-old patient admitted to the intensive care unit with acute respiratory failure, who had a history of COVID-19 infection five months prior to admission, despite having received certified vaccination. The patient developed NBTE involving the mitral valve, alongside acute respiratory distress syndrome (ARDS). In spite of the exclusion of cancer and systemic connective tissue disorders, the patient's condition rapidly deteriorated, leading to treatment-resistant multi-organ failure and demise, despite aggressive management, including anticoagulation therapy, mechanical ventilation, and renal replacement therapy. This case underscores the need for further research into the mechanisms underlying NBTE in the absence of traditional risk factors. Additionally, it highlights the importance of long-term anticoagulant therapy in NBTE management to mitigate the risk of embolic complications. Our case contributes to the growing body of literature identifying a subset of NBTE cancer-free patients with distinct characteristics, including those associated with current or past COVID-19 infection.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Notably, lung cancer stands out as the predominant cause of cancer-associated NBTE (Ca-NBTE) [3][4][5]. Recent studies have indicated a significant association between COVID-19 and infectioninduced hypercoagulation persisting up to 180 days after the initial infection [6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Non-bacterial Thrombotic Endocarditis (NBTE) in the Absence of Malignancy or Lupus Anticoagulant/Antiphospholipid Antibodies: A Case Report

Patrzałek,

Zawada,

Stolarski

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…SARS-CoV-2 can lead to increased expression of clotting factors and a simultaneous decrease in antithrombotic capabilities, which, combined with endothelial damage and vascular inflammation, creates favorable conditions for the formation of blood clots. These clots can subsequently block the coronary arteries, leading to a myocardial infarctions [26,27].…”

Section: Thrombosismentioning

confidence: 99%

The impact of the COVID-19 pandemic on the incidence of myocardial infarctions: an overview of current research

Roman,

Gondko,

Dębiec

et al. 2024

J Educ Health Sport

View full text Add to dashboard Cite

Introduction and Purpose: The COVID-19 pandemic has posed significant challenges to healthcare systems worldwide, particularly impacting the management of critical non-COVID conditions such as myocardial infarction (MI). This review aims to explore the alterations in the management of MI during the pandemic and assess how these changes have influenced patient outcomes. State of Knowledge: Numerous studies have reported delays in MI treatment during the pandemic due to healthcare resource reallocation towards COVID-19 care and patient hesitance in seeking timely medical help. Innovations such as telemedicine have been integrated into patient care to overcome barriers. However, these changes have varied impacts on clinical outcomes, including increased mortality and complication rates among MI patients during the pandemic. This review consolidates findings from recent studies focusing on altered treatment protocols, patient care strategies, and overall health system response during this period. Summary: The management of myocardial infarction during the COVID-19 pandemic has witnessed substantial shifts, leading to both challenges and innovations in cardiac care. While some adjustments have provided temporary solutions, the overall impact on MI outcomes has highlighted the need for more resilient healthcare strategies that ensure the continuity of care for acute cardiac events during global health emergencies.

show abstract

“…Over the past few years, this problem has become even more acute. Thromboembolic disorders have become one of the most serious clinical manifestations of COVID-19, leading to complications of the disease, as well as increased mortality [ 3 , 4 ]. Moreover, the risk of blood clots remains high months after the illness.…”

Section: Introductionmentioning

confidence: 99%

“…C;1 H NMR (400 16. MHz, DMSO-d 6 ), δ (ppm): 0.75 (3H, s, C 6 -CH 3 ); 1.60 (3H, s, C 4 -CH 3 ); 1.69 (3H, s, C4 -CH 3 ); 2.11 (1H, d, J = 14.3 Hz, C 5 -H); 2.46 (1H, d, J = 14.4 Hz, C 5 -H); 3.81 (3H, s, CH 3 O), 6.75 (1H, s, C=CH); 7.14 (2H, d, J = 8.7 Hz, CHarom); 7.34 (2H, d, J = 8.8 Hz, CHarom); 7.48-7.51 (2H, m, CHarom); 13.34 (1H, br.s, NH). 13 C NMR, δ (ppm): 24.7, 24.7, 27.5, 30.0, 50.7, 52.5, 52.6, 53.9, 115.6, 115.6, 119.4, 119.5, 120.4, 126.8, 127.6, 128.2, 128.5, 130.2, 130.2, 130.9, 139.5, 141.9, 146.0, 146.3, 155.7, 165.8, 166.2, 167.4.…”

mentioning

confidence: 99%

Design, Synthesis, and Evaluation of New Hybrid Derivatives of 5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-one as Potential Dual Inhibitors of Blood Coagulation Factors Xa and XIa

Skoptsova,

Geronikaki,

Novichikhina

et al. 2024

Molecules

View full text Add to dashboard Cite

Cardiovascular diseases caused by blood coagulation system disorders are one of the leading causes of morbidity and mortality in the world. Research shows that blood clotting factors are involved in these thrombotic processes. Among them, factor Xa occupies a key position in the blood coagulation cascade. Another coagulation factor, XIa, is also a promising target because its inhibition can suppress thrombosis with a limited contribution to normal hemostasis. In this regard, the development of dual inhibitors as new generation anticoagulants is an urgent problem. Here we report the synthesis and evaluation of novel potential dual inhibitors of coagulation factors Xa and XIa. Based on the principles of molecular design, we selected a series of compounds that combine in their structure fragments of pyrrolo[3,2,1-ij]quinolin-2-one and thiazole, connected through a hydrazine linker. The production of new hybrid molecules was carried out using a two-stage method. The reaction of 5,6-dihydropyrrolo[3,2,1-ij]quinoline-1,2-diones with thiosemicarbazide gave the corresponding hydrazinocarbothioamides. The reaction of the latter with DMAD led to the target methyl 2-(4-oxo-2-(2-(2-oxo-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1(2H)-ylidene)hydrazineyl)thiazol-5(4H)-ylidene)acetates in high yields. In vitro testing of the synthesized molecules revealed that ten of them showed high inhibition values for both the coagulation factors Xa and XIa, and the IC50 value for some compounds was also assessed. The resulting structures were also tested for their ability to inhibit thrombin.

show abstract

Risk of Thrombosis during and after a SARS-CoV-2 Infection: Pathogenesis, Diagnostic Approach, and Management

Cited by 21 publications

References 82 publications

Non-bacterial Thrombotic Endocarditis (NBTE) in the Absence of Malignancy or Lupus Anticoagulant/Antiphospholipid Antibodies: A Case Report

Non-bacterial Thrombotic Endocarditis (NBTE) in the Absence of Malignancy or Lupus Anticoagulant/Antiphospholipid Antibodies: A Case Report

The impact of the COVID-19 pandemic on the incidence of myocardial infarctions: an overview of current research

Design, Synthesis, and Evaluation of New Hybrid Derivatives of 5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-one as Potential Dual Inhibitors of Blood Coagulation Factors Xa and XIa

Contact Info

Product

Resources

About